CA2360124A1 - Regulation of anaesthesia - Google Patents

Regulation of anaesthesia Download PDF

Info

Publication number
CA2360124A1
CA2360124A1 CA002360124A CA2360124A CA2360124A1 CA 2360124 A1 CA2360124 A1 CA 2360124A1 CA 002360124 A CA002360124 A CA 002360124A CA 2360124 A CA2360124 A CA 2360124A CA 2360124 A1 CA2360124 A1 CA 2360124A1
Authority
CA
Canada
Prior art keywords
dsip
anaesthesia
anaesthetic
activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002360124A
Other languages
English (en)
French (fr)
Inventor
Christopher John Douglas Pomfrett
Michael Alkire
Richard Haier
Jim Fallon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902469.7A external-priority patent/GB9902469D0/en
Application filed by Individual filed Critical Individual
Publication of CA2360124A1 publication Critical patent/CA2360124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002360124A 1999-02-05 2000-02-01 Regulation of anaesthesia Abandoned CA2360124A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9902469.7 1999-02-05
GBGB9902469.7A GB9902469D0 (en) 1999-02-05 1999-02-05 Brain metabolism
US12032699P 1999-02-17 1999-02-17
US60/120,326 1999-02-17
US15566199P 1999-09-24 1999-09-24
US60/155,661 1999-09-24
PCT/GB2000/000281 WO2000045832A2 (en) 1999-02-05 2000-02-01 Regulation of anaesthesia

Publications (1)

Publication Number Publication Date
CA2360124A1 true CA2360124A1 (en) 2000-08-10

Family

ID=27269636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360124A Abandoned CA2360124A1 (en) 1999-02-05 2000-02-01 Regulation of anaesthesia

Country Status (15)

Country Link
EP (1) EP1148887A2 (zh)
JP (1) JP2002536337A (zh)
KR (1) KR20010101992A (zh)
CN (1) CN1346278A (zh)
AP (1) AP2001002245A0 (zh)
AU (1) AU2445900A (zh)
BR (1) BR0008046A (zh)
CA (1) CA2360124A1 (zh)
ID (1) ID30518A (zh)
IL (1) IL144572A0 (zh)
MX (1) MXPA01007949A (zh)
NO (1) NO20013795D0 (zh)
OA (1) OA11758A (zh)
TR (1) TR200102265T2 (zh)
WO (1) WO2000045832A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275308A1 (en) * 2001-07-13 2003-01-15 The Procter & Gamble Company Food composition offering stress relaxation to mammals
US20100210540A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
GB201116271D0 (en) * 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
CN108376559B (zh) * 2018-02-28 2020-10-16 复旦大学附属中山医院 乙醛脱氢酶2基因型在麻醉剂量计算中的应用
CN112535727A (zh) * 2020-12-24 2021-03-23 安域生物制药(杭州)有限公司 一种具有睡眠改善作用的短肽凝胶及其制备方法
CN112908454B (zh) * 2021-02-26 2023-08-29 西安交通大学口腔医院 一种智能保管麻醉剂的方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH634331A5 (de) * 1977-06-30 1983-01-31 Hoffmann La Roche Phosphorylierte nonapeptide und verfahren zu deren herstellung.
CA1188989A (en) * 1981-05-21 1985-06-18 Richard R. Scherschlicht Nonapeptide for the treatment of drug withdrawal symptoms
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
RU2104717C1 (ru) * 1995-07-07 1998-02-20 Новокузнецкий государственный институт усовершенствования врачей Способ анестезии при операциях у больных с синдромом лериша

Also Published As

Publication number Publication date
ID30518A (id) 2001-12-13
IL144572A0 (en) 2002-05-23
WO2000045832A2 (en) 2000-08-10
MXPA01007949A (es) 2003-06-04
AU2445900A (en) 2000-08-25
WO2000045832A3 (en) 2000-11-30
OA11758A (en) 2005-07-19
NO20013795L (no) 2001-08-02
EP1148887A2 (en) 2001-10-31
AP2001002245A0 (en) 2001-09-30
JP2002536337A (ja) 2002-10-29
BR0008046A (pt) 2001-11-06
CN1346278A (zh) 2002-04-24
KR20010101992A (ko) 2001-11-15
TR200102265T2 (tr) 2001-12-21
NO20013795D0 (no) 2001-08-02

Similar Documents

Publication Publication Date Title
US6562855B1 (en) Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist
JP5863650B2 (ja) 疼痛を処置するための方法
Thomas et al. Epidural dexamethasone reduces postoperative pain and analgesic requirements
WO2002089794A1 (en) Method for treating neuropathic pain and pharmaceutical preparation therefor
JP2003529541A6 (ja) ＮＭＤＡ拮抗薬とα２アドレナリン作用薬とを含む麻酔製剤
US5432176A (en) Method of retarding the progression of chronic renal failure
Cunningham et al. Dissociation of experimentally induced drinking behavior by ibotenate injection into the median preoptic nucleus
Grutzner et al. Effect of injury on pulpal levels of immunoreactive substance P and immunoreactive calcitonin gene-related peptide
CA2360124A1 (en) Regulation of anaesthesia
Park et al. Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
US6437093B1 (en) Methods of treatment comprising administration of Substance P
ZA200106256B (en) Regulation of anaesthesia.
Nimmo et al. Effect of anaesthesia and surgery on pharmacokinetics and pharmacodvamics
Collin et al. Feedback inhibition of met‐enkephalin release from the rat spinal cord in vivo
Mitchell et al. The long-term effect of epidural administration of butamben suspension on nerve injury-induced allodynia in rats
US20050032840A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
AU2001296493B2 (en) Use of neuropeptide-Y antagonists in treatment of alcoholism
McCleane Cholecystokinin and its antagonists in pain management
Van Dijk et al. Changes in heart rate, mean arterial pressure, blood biochemistry, plasma glucose, plasma lactate and some plasma enzymes during sufentanil/halothane anaesthesia in horses
Poli et al. Functional interactions between adenosine A1 and class II of metabotropic glutamate receptors in rat hippocampus
Chaiyakul Interactive effects of lidocaine and dextromethorphan in animal analgesia models
Guindon et al. The antinociceptive effects of local injections of propofol are mediated by cannabinoid CB1 and CB2 receptors: A-599
Kang Neurochemical and Behavioural Changes Foiiowing Propofol Anesthesia in the Rat.
Maldonado et al. Treatment of Opiate Withdrawal

Legal Events

Date Code Title Description
FZDE Discontinued